Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement

被引：7

作者：

Guerini-Rocco, Elena ^{[1
,2
]}

Botti, Gerardo ^{[3
]}

Foschini, Maria Pia ^{[4
]}

Marchio, Caterina ^{[5
,6
]}

Mastropasqua, Mauro Giuseppe ^{[7
]}

Perrone, Giuseppe ^{[8
]}

Roz, Elena ^{[9
]}

Santinelli, Alfredo ^{[10
]}

Sassi, Isabella ^{[11
]}

Galimberti, Viviana ^{[12
]}

Gianni, Luca ^{[13
]}

Viale, Giuseppe ^{[1
,2
]}

机构：

[1] European Inst Oncol IRCCS, Div Pathol, IEO, Via G Ripamonti 435, I-20141 Milan, Lombardy, Italy

[2] Univ Milan, Dept Oncol & Hematooncol, Via G Ripamonti 435, I-20141 Milan, Lombardy, Italy

[3] Ist Nazl Tumori IRCCS Fdn G Pascale, Sci Direct, Naples, Italy

[4] Univ Bologna, Unit Anat Pathol M Malpighi, Dept Biomed & Neuromotor Sci, DIBINEM,Bellaria Hosp, Bologna, Italy

[5] FPO IRCCS, Candiolo Canc Inst, Candiolo, Italy

[6] Univ Turin, Dept Med Sci, Turin, Italy

[7] Univ Bari Aldo Moro, Sch Med, Dept Emergency & Organs Transplantat, Sect Anat Pathol, Bari, Italy

[8] Campus Biomed Univ, Res Unit Pathol, Rome, Italy

[9] La Maddalena Clin Canc, Pathol Unit, Palermo, Italy

[10] Azienda Osped Osped Riuniti Marche Nord, Anat Pathol, Pesaro, Italy

[11] San Raffaele Univ & Res Hosp, Pathol Unit, Milan, Italy

[12] European Inst Oncol IRCCS, Div Breast Surg, IEO, Milan, Italy

[13] Fdn Gianni Bonadonna, Milan, Italy

来源：

TUMORI JOURNAL | 2022年 / 108卷 / 03期

关键词：

Pathologic response; neoadjuvant therapy; breast cancer; consensus; RESIDUAL DISEASE; CLINICAL-TRIALS; RECEPTOR STATUS; STAGING SYSTEM; CHEMOTHERAPY; SURVIVAL; HORMONE; BURDEN; RECOMMENDATIONS; EXPRESSION;

D O I：

10.1177/03008916211062642

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pathologic evaluation of early breast cancer after neoadjuvant therapy is essential to provide prognostic information based on tumor response to treatment (pathologic complete response [pCR] or non-pCR) and to inform therapy decisions after surgery. To harmonize the pathologist's handling of surgical specimens after neoadjuvant therapy, a panel of experts in breast cancer convened to developed a consensus on six main topics: (1) definition of pCR, (2) required clinical information, (3) gross examination and sampling, (4) microscopic examination, (5) evaluation of lymph node status, and (6) staging of residual breast tumor. The resulting consensus statements reported in this document highlight the role of an accurate evaluation of tumor response and define the minimum requirements to standardize the assessment of breast cancer specimens after neoadjuvant therapy.

引用

页码：196 / 203

页数：8

共 53 条

[1]

AIOM, 2021, RACC POS PAP

[2]

AIOM, AIOM GUID BREAST NEO

[3]

Amin MB., 2017, Ajcc Cancer Staging Manual, V8th ed

[4] Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration [J].

Bossuyt, V. ;

Provenzano, E. ;

Symmans, W. F. ;

Boughey, J. C. ;

Coles, C. ;

Curigliano, G. ;

Dixon, J. M. ;

Esserman, L. J. ;

Fastner, G. ;

Kuehn, T. ;

Peintinger, F. ;

von Minckwitz, G. ;

White, J. ;

Yang, W. ;

Badve, S. ;

Denkert, C. ;

MacGrogan, G. ;

Penault-Llorca, F. ;

Viale, G. ;

Cameron, D. .

ANNALS OF ONCOLOGY, 2015, 26 (07) :1280-1291

[5] Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long-term outcomes for breast cancer patients [J].

Bossuyt, Veerle ;

Spring, Laura .

BREAST JOURNAL, 2020, 26 (06) :1189-1198

[6] Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 [J].

Burstein, H. J. ;

Curigliano, G. ;

Loibl, S. ;

Dubsky, P. ;

Gnant, M. ;

Poortmans, P. ;

Colleoni, M. ;

Denkert, C. ;

Piccart-Gebhart, M. ;

Regan, M. ;

Senn, H. -J. ;

Winer, E. P. ;

Thurlimann, B. .

ANNALS OF ONCOLOGY, 2019, 30 (10) :1541-1557

[7] Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives [J].

Caparica, Rafael ;

Lambertini, Matteo ;

Ponde, Noam ;

Fumagalli, Debora ;

de Azambuja, Evandro ;

Piccart, Martine .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11

[8]

College of American Pathologists, 2018, PROTOCOL EXAMINATION

[9] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[10]

ELLIS IO, 1992, HISTOPATHOLOGY, V20, P479

← 1 2 3 4 5 6 →